Obesity care is at a crossroads, and Australia is poised to make a pivotal decision that could reshape how we tackle this growing health crisis. The impending PBS listing of Wegovy, a GLP-1 medication, has sparked both excitement and caution among experts. While this move could democratize access to a revolutionary treatment, it also exposes a glaring gap in our healthcare system: the lack of comprehensive support for patients navigating obesity care. What makes this particularly fascinating is how it highlights the tension between medical innovation and the practical realities of delivering sustainable health outcomes.
From my perspective, the real story here isn’t just about making GLP-1s more affordable—it’s about what happens after patients get the prescription. Obesity care isn’t a one-and-done solution; it’s a complex, ongoing process that requires multidisciplinary support. Diet, exercise, and behavioral changes are just as critical as the medication itself. Yet, what many people don’t realize is that the current Chronic Condition Management Plans (CCMPs) under Medicare fall woefully short in addressing these needs.
The CCMP model, while effective for some chronic conditions, feels like a square peg in a round hole when it comes to obesity. One thing that immediately stands out is the rigid cap of five allied health services per year. For someone starting GLP-1 therapy, this is barely enough to scratch the surface. The early stages of treatment are often the most challenging, with side effects and lifestyle adjustments demanding frequent, low-intensity support. If you take a step back and think about it, this limitation isn’t just inconvenient—it’s a barrier to success.
Another glaring issue is the model’s reliance on in-person GP consultations. A detail that I find especially interesting is how this disproportionately affects rural and regional patients, who already face a 1.4 times higher burden of disease. Telehealth and asynchronous care models, which could bridge this gap, are largely excluded from the CCMP framework. What this really suggests is that our healthcare system is still clinging to outdated delivery models, even as technology offers more flexible, accessible alternatives.
Personally, I think the exclusion of pharmacists and nurses from the list of eligible providers is a missed opportunity. These professionals are often the first point of contact for patients, offering critical guidance on medication management and side effects. Their absence from the CCMP framework underscores a broader issue: our healthcare system isn’t designed to leverage the full potential of multidisciplinary care.
This raises a deeper question: Are we investing in treatments without investing in the systems that make them work? The PBS listing of Wegovy is a significant step forward, but without wraparound care, it risks becoming a costly experiment in half-measures. Patients who discontinue treatment due to lack of support will likely regain weight, undermining both individual health and the economic benefits of the investment.
In my opinion, the solution lies in modernizing the CCMP framework to better align with the realities of obesity care. This could include expanding service delivery models to include asynchronous care, increasing the cap on allied health services, and broadening the range of eligible providers. What makes this particularly fascinating is how these changes could set a precedent for managing other complex chronic conditions, not just obesity.
If you take a step back and think about it, this isn’t just about healthcare policy—it’s about equity. Effective obesity care has the potential to reduce the staggering economic burden of the disease, estimated to rise to $87.7 billion by 2032. But to achieve this, we need a system that supports patients every step of the way, not just at the pharmacy counter.
From my perspective, the PBS listing of Wegovy is a golden opportunity to rethink how we approach chronic disease management. It’s a chance to move beyond siloed treatments and embrace holistic, patient-centered care. What this really suggests is that the future of healthcare isn’t just about what medications we develop, but how we deliver them.
As we stand on the brink of this transformation, one thing that immediately stands out is the urgency of the moment. Obesity isn’t just a health issue—it’s a societal one. By rethinking the CCMP framework, we can ensure that innovations like GLP-1s aren’t just accessible, but effective. Personally, I think this is the kind of bold, forward-thinking approach we need to tackle one of the most pressing health challenges of our time.
